<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151366">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01923389</url>
  </required_header>
  <id_info>
    <org_study_id>B2901009</org_study_id>
    <nct_id>NCT01923389</nct_id>
  </id_info>
  <brief_title>Multiple Dose Study Of PF-05231023 In Obese Adult Subjects</brief_title>
  <official_title>A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenous Doses Of PF-05231023 In Obese Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and
      pharmacodynamics of multiple doses of PF-05231023.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated on December 19th, 2013 due to a business decision by the Sponsor.  No
    safety concerns have been observed in this study.
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Incidence and severity of all causality Adverse Events and treatment-emergent Adverse Events, ECG parameters, SBP, DBP, Pulse Rate, Laboratory trends and incidence of abnormalities per Sponsor's safety reporting standards.</measure>
    <time_frame>68 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-PF-05231023 antibodies and neutralizing antibodies</measure>
    <time_frame>68 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK of PF-05231023 after multiple intravenous doses including Cmax and Cmin</measure>
    <time_frame>68 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of sub-components of PF-05231023 including AUCtau, Cmax, Tmax after a single dose and  accumulation ratio (AUC and Cmax), Cmin and Cav after the last dose</measure>
    <time_frame>68 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Type 2 Diabetes Mellitus (T2DM)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg PF-05231023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg PF-05231023</intervention_name>
    <description>100 mg IV infusion twice a week for 4 weeks</description>
    <arm_group_label>100 mg PF-05231023</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects of non-childbearing potential between the ages of 21 and 70.

          -  Subjects with a BMI of 30 to 45.4 kg/m2 and total body weight &gt;110 lbs.

        Exclusion Criteria:

          -  Recent (6 months) unstable concurrent disease.

          -  History of allergic disease or drug allergies.

          -  Any condition affecting food consumption or absorption.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2901009&amp;StudyName=Multiple%20Dose%20Study%20Of%20PF-05231023%20In%20Obese%20Adult%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T2DM</keyword>
  <keyword>obesity</keyword>
  <keyword>safety</keyword>
  <keyword>multiple dose</keyword>
  <keyword>intravenous</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
